SQSTM1 and neoplasm: Unlike the roles of p62 in tumor initiation and progression, our findings imply the clinical significance of p62 targeting in terms of heterogeneous tumor treatment, providing an integrative understanding of p62 as a major determinant of the reactivity to cancer therapy.